• In May 2026, Viatris Inc. reported first-quarter revenue of US$3,517.0 million and net income of US$176.4 million, and the FDA accepted for review its New Drug Application for MR-107A-02, a fast-acting meloxicam formulation for moderate-to-severe acute pain with a PDUFA goal date of December 27, 2026.
• The fast-acting meloxicam NDA, backed by Phase 3 data showing pain relief and reduced opioid use, highlights Viatris’ push into higher-value, clinically differentiated medicines alongside its improving quarterly profitability.
• We’ll now examine how the fast-acting meloxicam filing and improving earnings profile may influence Viatris’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Viatris Investment Narrative Recap

To own Viatris, you need to believe that its shift from a heavily generic, off patent base toward more value added drugs can steadily improve earnings quality, even under pricing pressure and regulatory scrutiny. The fast acting meloxicam NDA adds a visible non opioid pain candidate to that effort, but the main near term catalyst remains consistent execution against 2026 guidance, while the biggest risk is that generics price erosion and regulatory changes continue to weigh on margins.

The most relevant recent announcement here is Viatris’ reaffirmed 2026 revenue guidance of US$14,450 million to US$14,950 million, issued alongside its return to positive quarterly net income. Together with the meloxicam filing, this guides the story toward whether Viatris can turn a still largely mature, price pressured portfolio into a more profitable mix that includes differentiated products, without losing ground to lower cost competitors or running into further operational setbacks.

Yet beneath the improving earnings and new filings, investors should also be aware that...

Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1.25 billion earnings increase from -$296.5 million today.

Uncover how Viatris' forecasts yield a $17.50 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Viatris could lift revenue to about US$15.9 billion and earnings to roughly US$2.3 billion by 2029, which is a far more upbeat view than the consensus that focuses on pricing and execution risks; with the fast acting meloxicam news now on the table, you can judge for yourself whether that bullish scenario or the more cautious narrative feels closer to how you see the company’s future.

Explore 7 other fair value estimates on Viatris - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.